Hyponatremia in cancer patients: time for a new approach

Highlights • Hyponatremia is relevant in cancer patients because it may have a negative impact on outcome, on quality of life and on length of hospitalization. • There are evidences that the inappropriate antidiuretic hormone syndrome (SIADH) is the most common cause of hyponatremia in cancer patien...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2016-06, Vol.102, p.15-25
Main Authors: Rossana, Berardi, Silvia, Rinaldi, Miriam, Caramanti, Christian, Grohè, Matteo, Santoni, Francesca, Morgese, Mariangela, Torniai, Agnese, Savini, Ilaria, Fiordoliva, Stefano, Cascinu
Format: Article
Language:English
Subjects:
Antidiuretic hormone
Cancer
Chronic Disease
Hematology, Oncology and Palliative Medicine
Humans
Hyponatremia
Hyponatremia - etiology
Hyponatremia - physiopathology
Hyponatremia - therapy
Neoplasms - complications
SIADH
Sodium
Vasopressin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Hyponatremia is relevant in cancer patients because it may have a negative impact on outcome, on quality of life and on length of hospitalization. • There are evidences that the inappropriate antidiuretic hormone syndrome (SIADH) is the most common cause of hyponatremia in cancer patients. • An early detection, monitoring and prompt management is needed to improve the patient’s outcome and several options are available. • Several studies have demonstrated the efficacy and good tolerability of Tolvaptan for the treatment of SIADH-related hyponatremia even in cancer patients.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2016.03.010